公开(公告)号：US20180360881A1

公开(公告)日：2018-12-20

申请号：US15781428

申请日：2016-12-09

Applicant: NANT HOLDINGS IP, LLC ,  NANTCELL, INC. ,  NANTKWEST, INC.

Inventor： Shahrooz Rabizadeh ,  Patrick Soon-Shiong ,  Hans Klingemann

IPC: A61K35/17 ,  A61P35/00 ,  A61K31/337 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

Abstract: Contemplated immunotherapies include co-administration of an activated NK cell that is further genetically modified and a cancer therapeutic agent. In preferred embodiments, activated NK cells are further modified to taNK cells, which include a chimeric antigen receptor (CAR) with affinity for a cancer specific antigen, a cancer associated antigen, or a tumor specific antigen. Activated NK cells can also be further genetically modified to include high affinity Fc receptor CD16a (V158). Appropriate cancer therapeutic agents include chemotherapeutic drugs (e.g., nant-paclitaxel) or cancer targeted antibodies (e.g., trastuzumab).

公开(公告)号：US11221328B2

公开(公告)日：2022-01-11

申请号：US16491559

申请日：2018-03-07

Applicant: NANTCELL, INC.

Inventor： Patrick Soon-Shiong ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Stephen Charles Benz ,  Laurent H. Boissel ,  Hans Klingemann ,  Barry J. Simon

IPC: C12Q1/6886 ,  G01N33/50 ,  G16H50/30 ,  C12N5/0783

Abstract: Detection of under-expression of selected genes in NK cells is used to confirm a hypoxic tumor microenvironment that is ordinarily suppressive with respect to ADCC and cytotoxic cell killing of NK cells. Most notably, while hypoxia is known to upregulate HIF-1α and genes under the control of HIF-1α, hypoxia in a tumor microenvironment led to under-expression of selected genes, including HIF-1α. Thus, gene expression analysis of certain genes on NK cells can be used to detect conditions in a tumor that would indicate use of haNK cells.